Chase Science's reinvestment for growth seems ineffective as sales remain stagnant, leading to concerns over diminishing returns. The decrease in ROCE may be due to the company funding more operations with its own money, potentially reducing efficiency.

Investors remain bullish on Chase Science despite its high P/E ratio, possibly due to expectations of outperforming the market. However, the company's recent earnings trends suggest these prices may not be sustainable, especially with a forecasted market expansion of 41%.

Chase Science's low ROE, despite high profit retention and earnings growth, suggests investors may not fully benefit from reinvestment. Its growth is below industry average, indicating potential risks. Further risk assessment is advised before investing.

Chase Science's high P/E ratio is alarming given its receding earnings and weak performance in the market. A trend continuation of recent earnings could impact share price, potentially explaining bearish investor sentiment.